Advanced Dual-Isotope Imaging Reveals How Antibody-Drug Conjugates Deliver Payloads to Tumors

Groundbreaking cryoimaging technology tracks both antibody and drug distribution in real-time, transforming ADC development

Understanding exactly where antibody-drug conjugates (ADCs) go and how they release their toxic payloads has been one of the biggest challenges in cancer drug development. This pioneering research introduces a powerful new imaging methodology that solves this problem by tracking both the antibody and the drug simultaneously with unprecedented detail.

Using innovative dual-isotope cryoimaging combined with 3D visualization, researchers successfully demonstrated how ADCs penetrate tumors, release their cytotoxic drugs, and achieve the critical “bystander effect” that kills cancer cells lacking the target antigen. The study of TAK-264, targeting guanylyl cyclase C in colorectal cancer models, revealed that successful drug release could be quantified by measuring the separation of antibody and payload signals over time.

Why Read this Publication:

• First-of-its-kind technology: Learn about a novel dual-isotope imaging approach that simultaneously tracks antibody and drug components with cellular-level resolution
• Quantify drug release: Discover methods to measure when and where ADC payloads separate from their antibody carriers in tumor tissue
• Optimize ADC design: Understand how imaging data can inform linker chemistry, dosing strategies, and target selection for more effective ADCs
• Visualize bystander effects: See direct evidence of how released drugs diffuse beyond targeted cells to eliminate neighboring cancer cells
• Translatable methodology: Explore techniques applicable across ADC platforms to accelerate preclinical and clinical development

Learn more about Perceptive Discovery’s preclinical oncology services here